Drug data last refreshed 13h ago · AI intelligence enriched 2w ago
POLYCILLIN-PRB is an oral suspension combining ampicillin (a beta-lactam antibiotic) with probenecid (a uricosuric agent that increases ampicillin serum levels by inhibiting renal excretion). This combination enhances ampicillin bioavailability and is indicated for bacterial infections where elevated antibiotic concentrations are therapeutically beneficial. The product targets patients requiring optimized ampicillin exposure with reduced dosing frequency.
Pre-launch stage indicates opportunity for early-stage brand building, launch team assembly, and market development roles at Bristol Myers Squibb.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on POLYCILLIN-PRB offers entry or advancement in launch-phase pharmaceutical management, providing exposure to brand building, market development, and specialty antibiotic positioning at a major pharmaceutical company. This pre-launch asset presents career opportunity in orchestrating market entry strategy and establishing brand identity in a niche therapeutic area.
Worked on POLYCILLIN-PRB at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.